A Phase 2 study of mevidalen in Alzheimer's disease

Completed Phase 2 NCT06538116

Study Description

A study to evaluate the safety and effectiveness of mevidalen in improving symptoms of mild to moderate Alzheimer's disease

Study Details

Registry ID:
NCT06538116
Conditions:
Alzheimer Disease
Phase:
Phase 2
Target Enrollment:
304 participants
Start Date:
Age Range:
50–80 years
Healthy Volunteers:
No

Study Locations (110 sites)

Interested in Participating?

Check your eligibility and learn more about this study on TrialScreen.

View full study details and check eligibility →